Bifurcation Management Update:

Slides:



Advertisements
Similar presentations
Randomized Comparison of Provisional Side Branch Stenting versus a Two-stent Strategy for treatment of True Coronary Bifurcation Lesions Involving a Large.
Advertisements

Eight Months Angiographic Follow-up in Patients Randomized to Crush or Culotte Stenting of Coronary Artery Bifurcation Lesions The Nordic Bifurcation Stent.
Www. Clinical trial results.org  Major Endpoints: Death, MI, stent thrombosis, TLR, TVR, MACE, and CKMB >3x nl  Major Endpoints: Death, MI, stent thrombosis,
Bifurcation Overview A comprehensive overview of Bifurcation disease, treatment options and techniques.
Bifurcation coronary stenting: State 0f the Art Mazhar M Khan Consultant Cardiologist Royal Victoria Hospital Belfast, N.Ireland.
BIFURCATION LESIONS Dr. Tahsin.N
29th ANNUAL SCIENTIFIC SESSIONS – SCA&I
Bifurcation Stenting: A primer
Tips and Pitfalls in Measurement of FFR during Bifurcation Stenting Nanjing first hospital Nanjing cardiovascular hospital Yefei Chenshaoliang Zhangjunjie.
For the Nordic-Baltic PCI Study Group
FRONTIER Registry The Guidant MULTI-LINK FRONTIER ™ Coronary Stent System for the Treatment of Pts with Native De Novo or Restenotic Bifurcation Coronary.
TCT 2012 Revascularization Strategies for Complex Left Main Disease and Left Coronary Ostial Disease Alfredo E. Rodriguez, MD, PhD, FACC, FSCAI Centro.
左主干分叉病变治疗策略的选择 Left main bifurcation: what is the best choice? Lei Ge, MD Department of Cardiology, Zhongshan Hospital, Fudan University.
A Prospective, Randomized Trial Evaluating a Paclitaxel-Eluting Balloon in Patients TReated with Endothelial Progenitor Cell CapTuring Stents for De Novo.
Treatment of bifurcation lesions is a complex problem Different techniques are commonly used (Y-/T-stenting, „culotte“ technique, „kissing stent“ technique…)
J Hermiller MD 1 Bifurcation Lesion Treatment Option: Insights From Clinical Literature James Hermiller, MD, FACC, FSCAI St Vincent Medical Group St Vincent.
Dedicated Bifurcation Stent Technology: Implications for Everyday Practice Jens Flensted Lassen MD, PH.D., FESC The Heart Centre, Rigshospitalet University.
Is there any role for intravascular ultrasound in bifurcation lesions? Giuseppe Biondi-Zoccai, MD University of Turin, Turin, Italy.
Ms. Leonardo Roever Coronary Stents. Coronary Artery Disease Leading cause of death in United States for men and women Caused by buildup of plaque in.
Influence of a Pressure Gradient Distal to Implanted Bare-Metal Stent on In-Stent Restenosis After Percutaneous Coronary Intervention Lisette Okkels Jensen,
Philippe Généreux, MD for the Tryton Bifurcation Trial Investigators Columbia University Medical Center Cardiovascular Research Foundation New York City.
Intravascular ultrasound (IVUS) in the treatment of long and diffuse lesions– summary of key articles Prepared by Radcliffe Cardiology 21 November2016.
Martin B. Leon, MD Key Messages Tryton Pivotal: Randomized Trial and
Novel Trial Design Focus - Left Main and “All Comers” DES Studies: All-Comers Studies. Interventional View Jeffrey J. Popma, MD Director, Innovations in.
Techniques, Outcome and New Devices
Everolimus-eluting Bioresorbable Vascular Scaffolds in Patients with Coronary Artery Disease: ABSORB III Trial 2-Year Results Stephen G. Ellis, MD,
Clinical Trials and Outcomes with DES in CTO Revascularization
What should be the optimal Design for TAVI Procedure.
Percutaneous coronary angioplasty versus coronary artery bypass grafting in treatment of unprotected left main stenosis Nordic–Baltic–British left main.
Will we ever see a dedicated bifurcated DES in clinical practice?
Disclosures Speaker’s bureau: Research support: Consulting: Equity
Stent Thrombosis and Optimal Duration of DAPT
Bifurcation Balloon & Stent Delivery System
Bifurcation PCI: Basic Techniques and Data from Clinical Trials
Regulatory Basics: Europe and the CE Mark
Are we ready to perform TAVI in Intermediate Risk Patients?
OUS Data: What does the CE Mark Really Mean?
For the Nordic-Baltic PCI Study Group
(DES)+BVS +DCB for long diffuse LAD disease
How to Handle a Complex Bifurcation Lesion
Paclitaxel Drug-Coated Balloons for De Novo Lesions
A Novel “Stent-On-A-Wire”Ultra Low Profile Stent Delivery System
Strategy planning in coronary bifurcation stenting
TAVI „Catch me if you can!“
David J. Cohen, M.D., M.Sc. Director of Cardiovascular Research
The Tryton Bifurcation Trial:
CRT 2010 Washington DC, January 21, 2010
Progress with the Sadra Medical Lotus™ Valve System
Debate: What Does the Future Hold for the Treatment of Unprotected Left Main Disease? More PCI No More Routine Surgery Ron Waksman, MD, FACC Washington.
DES Should be Used as the Default Stent in ACS!
The XIENCE V EXCEED Study
Subintimal Tracking and Reentry for CTO STAR Method
OCT-Guided PCI What needs to be done to establish criteria?
Stenting of Coronary Arteries in Non Stress/Benestent Disease
Three Years Follow Up. SORT OUT II
BBK II Trial design: Patients undergoing a two-stent approach for a de novo bifurcation lesion were randomized in a 1:1 fashion to either culotte stenting.
American College of Cardiology Presented by Dr. Stephan Windecker
Incidence And Management Of Restenosis After Treatment Of Unprotected Left Main Disease With Drug-Eluting Stents: 70 Restenotic Cases From A Cohort Of.
How and why this study may change my practice ?
Large-Scale Registry Examining Safety and Effectiveness of Zotarolimus-Eluting and Sirolimus-Eluting Stents in Patients with Coronary Artery Disease Western.
For the Nordic-Baltic PCI Study Group
Bifurcation Disease: Simulation Training Curriculum
Incidence and management of restenosis after treatment of unprotected left main disease with drug-eluting stents: 70 restenotic cases from a cohort of.
SORT-OUT III: A Prospective Randomized Comparison of Zotarolimus-Eluting and Sirolimus-Eluting Stents in Patients with Coronary Artery Disease Michael.
TAXUS – Myonecrosis and sidebranch patency concerns are short-term issues with no long-term consequences, and the benefits are undeniable Jeffrey J. Popma,
Long-term safety and efficacy of zotarolimus-eluting and sirolimus-eluting stents in routine clinical care patients 36-month follow-up in the SORT OUT.
Fadi J. Sawaya et al. JCIN 2016;9:
SMART-STRATEGY Trial design: Patients with a bifurcation coronary lesion were randomized to a conservative strategy (n = 128) vs. an aggressive strategy.
APPROACH TO CORONARY BIFURCATION LESIONS
Tanveer Rab et al. JCIN 2017;10:
Presentation transcript:

Bifurcation Management Update: CRT 2013 2012 Washington DC, February  Bifurcation Management Update: Choosing the Right Strategy and Technique Eberhard Grube MD FACC, FSCAI University Hospital Bonn, Germany Stanford University, School of Medicine, Palo Alto, CA Hospital Alemão Oswaldo Cruz, São Paulo, Brazil

Eberhard Grube, MD Consulting: Medtronic CoreValve, Boston Scientific Corporation, Cordis Corporation, Johnson and Johnson and Abbott Vascular Honoraria: Boston Scientific Corporation and Biosensors International Stocks, Stock Options, other ownership interest: Medtronic CoreValve and Biosensors International Off-Label: Off-label use of stents and valve prosthesis

Preamble The main limitation of all randomized studies comparing provisional versus routine double stenting is that bifurcation lesions which are randomized are most of the times suitable for provisional. Bifurcation lesions which need to be treated with two stents are usually not randomized. For bifurcation lesions, which are suitable for 1 stent or 2 stents, routine implantation of 2 stents does not give any advantage compared to routine implantation of 1 stent and cross-over to 2 stents when needed

My view If you decide to implant two stents you take more responsibilities : an optimal result will give you a low restenosis on the SB, a suboptimal result may increase the risk of thrombosis of the SB and sometimes of the MB. If you decide to implant one stent you are mainly responsible for the SB only: an incorrect decision may lead to SB closure The final decision is a balance between the clinical relevance of the SB (risk of occlusion) and how confident is the operator to obtain an optimal result

This is not an ideal lesion for a 1 vs. 2 stents trial

Bifurcations Provisional Keep It Open (KIO) Two stents

Provisional Wire both branches Dilate MB and SB if needed When the SB has minimal disease or disease at the ostium AND when the SB is suitable for stenting Wire both branches Dilate MB and SB if needed Stent MB leaving a wire in the SB Re-wire SB and then remove jailed wire Kissing balloon inflation Stent SB if suboptimal result (TAP is my preferred strategy to cross-over to 2 stents)

Keep It Open (KIO) Wire both branches Dilate MB if needed When the SB has ostial or diffuse disease AND when the SB is not suitable (too small) for stenting or clinically not relevant Wire both branches Dilate MB if needed Stent MB and leave wire in the SB Perform post-dilatation of the MB with jailed wire in the SB Do not re-wire SB or postdilate or predilate SB

Two Stent Approach Cross over from Provisional: TAP: T and protrusion 2 stents as Intention to Treat: Mini Crush, Culotte, V: only for very suitable anatomy

non-left main bifurcations Predictors of restenosis after one and two-stent techniques in left main and non-left main bifurcations 9 9

Colombo A. et al Circulation 2009;119:71-78. 10 10

If crush 2 step kiss ! 11 11

Inflate at high pressure only the SB balloon We observed that two-step kissing was more effective than one-step kissing for improving metallic side-branch ostial area No kissing One-step kissing post-dilatation Two-step kissing post-dilatation SB ostial stenosis (%) with one step vs. two step kissing 58 crush deployments Two steps: Inflate at high pressure only the SB balloon 2) Perform kissing inflation Ormiston 12

Influence of Final Kissing in the CACTUS trial YES Final Kissing 163 pts. NO Final Kissing 14 pts. P Myocardial infarction 7.5% 29% 0.001 TLR 6.3% 12.9% 0.25 MB restenosis 4.7% 16% 0.03 SB restenosis 11.9% 36% Stent thrombosis 0.9% 6.5% 0.06

For the Nordic-Baltic PCI Study Group Nordic-Baltic Bifurcation Study III Randomized Comparison of Final Kissing Balloon Dilatation vs. no Final Kissing Balloon Dilatation in Patients with Coronary Bifurcation Lesions Treated With Main Vessel stenting Matti Niemela, Kari Kervinen, Andrejs Erglis,Niels R. Holm, Michael Maeng, Evald H Christiansen, Indulis Kumsars, Sandra Jegere, Andis Dombrovskis, Pål Gunnes, Sindre Stavnes,TerjeS teigen,Thor Trovik, Saila Vikman,Markku Eskola, Hannu Romppanen,Timo Makikallio, Knud N Hansen, Per Thayssen, Lars Åberge,Lisette Jensen, Anders Hervold, J Airaksinen, Mikko Pietila, Ole Frobert, Thomas Kellerth, Jan Ravkilde,Jens Aarøe,Steffen Helqvist, Iwar Sjögren, Stefan James,Heikki Miettinen, Jens F Lassen, Leif Thuesen For the Nordic-Baltic PCI Study Group Andis Dombrovskis. 14

(Re)stenosis at 8-months QCA: Entire bifurcation lesion % p=0.11 17.3% 11.0% Binary Restenosis: ≥50% diameter stenosis at follow-up

(Re)stenosis: Ostial Side Branch % p=0.039 15.4% 7.9% Binary Restenosis: ≥50% diameter stenosis at follow-up

True bifurcation subgroup MACE and TLR at 6 month clinical FU 2.5% % (n=121) (n=118) 1.7% 1.7% P=0.68 0.8% P=0.62

BIFURCATION ANGLE and TECHNIQUE TO USE WITH 2 STENTS In general a small bifurcation angle gives a better result with mini-crush or culotte. A large angle with T or T and protrusion With 2 stents an appropriately performed final kiss minimizes the effect of the bifurcation angle Bifurcation angle Dzavik et al Am Heart J 2006;152:762-769

Bifurcation as predictor of DES thrombosis

Bifurcation and Thrombosis The association of bifurcation with DES thrombosis has been frequent but not consistent across the studies with DES Bifurcation has been related specially with early thrombosis or even with late 1-12 months but not with very late thrombosis The use of complex techniques (2 stents) could increase the risk of thrombosis, specially in the setting of ACS: operator dependent In ESTROFA-2, bifurcation was an independent predictor for early thrombosis: The treatment of bifurcations with ZES and with double stenting was associated with a trend for a higher risk (REGISTRY) In cases with bifurcations a lower EF and smaller stent diameter were close to result independent predictors for thrombosis In ACS, thrombosis was not significantly higher, though more frequently late

Dedicated bifurcation stents At the moment for true bifurcations with short lesions in the side branch when the operator does not feel confident to recross an unprotected side branch 6 month FU Cappella sideguard Tryton

Conclusions 1 The final result is far more important than the technique utilized IVUS check on both branches every time 2 stents are implanted

Conclusions 2 Stenting coronary bifurcations requires more than deciding to implant 1 or 2 stents The most important decisions should be taken by examining: the clinical setting the extent of the disease in both branches, their size the territory of distribution and how confident is the operator with a specific approach